Hoth Therapeutics Announces Positive Confirmatory Results of In Vivo Model of HT-003 Assets as Potential Acne Treatment
NEW YORK, July 13, 2021 / PR Newswire / Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-centric biopharmaceutical company, today announced that its HT-003 asset group has shown positive results in an in vivo therapeutic model of acne. The model showed that HT-003 reduced the expression of the toll-like receptor 2 (TLR2), one of the most critical pathways for the pathophysiology of acne. The study also showed that HT-003 reduced the expression of many cytokines essential to the pathophysiology of acne which are also relevant therapeutic markers for other inflammatory skin diseases.
HT-003 is a group of agents blocking the metabolism of retinoic acid (RAMBA), which are new agents that prevent the breakdown of retinoic acid. Retinoic acid acts as an anti-inflammatory agent in the body.
In the study, the skin of mice was topically pretreated with RAMBA or a non-clinical vehicle for two days. Then the skin was injected intradermally with peptidoglycan (PGN), which induces acne-like inflammation. The models demonstrated that the induction of PGN by TLR2 and a large list of inflammatory cytokines were inhibited in skin pretreated with RAMBA.
“The results of this study are extremely promising and suggest that this drug could both treat acne and may actually help prevent it,” said Dr. Jonathan zippin, MD, Ph.D., FAAD, associate professor of dermatology at Weill Cornell Medicine and senior scientific advisor to Hoth, who is leading the study. “The data also suggests that the HT-003 compounds have the potential for the treatment of many inflammatory skin diseases.”
In addition to the dermatological application, Hoth Therapeutics is exploring the potential application of HT-003 actives in inflammatory bowel disorders (IBD).
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation therapies for unmet medical needs. Hoth’s pipeline development aims to improve the quality of life of patients with indications such as atopic dermatitis, skin toxicities associated with cancer treatment, chronic wounds, psoriasis, asthma, acne, cancers derived from mast cells and anaphylaxis and pneumonia. Hoth has also entered into two different agreements to further develop two therapeutic perspectives to prevent or treat COVID-19. For more information, please visit https://ir.hottherapeutics.com/.
This press release includes forward-looking statements based on Hoth’s current expectations that may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws. securities, and are subject to substantial risks, uncertainties and assumptions. These statements relate to Hoth’s business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval for existing product candidates and any other product candidates we may develop, and labeling under any approvals we may obtain; the schedule and costs of clinical trials, the schedule and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, clinical trials, research programs, health systems, or the global economy as a whole; our intellectual property; our dependence on third party organizations; our competitive position; our industrial environment; our expected financial and operating results, including expected sources of revenue; our assumptions regarding the size of the available market, the benefits of our products, product pricing, timing of product launches; management’s expectations with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash flow requirements and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by these forward-looking statements. You should not rely on these forward-looking statements, which include words such as “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “could” , “Continue”, “foresee”, “potential”, “project” or similar terms, variations of these terms or the negative of these terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the The Company cannot guarantee such results. Hoth may not achieve its expectations and beliefs may not prove to be correct. Actual results may differ materially from those shown in these forward-looking statements due to various important factors, including, without limited thereto, market conditions and the factors described in the section entitled “Risk Factors” in Hoth’s most recent Annual Report on Form 10 -K and other documents filed by Hoth with the Securities and Exchange Clerk. tion of the United States. All such statements are only valid on the date on which they are made. Therefore, forward-looking statements should be viewed only as Hoth’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, activity levels, performance or achievements. Hoth does not undertake and specifically disclaims any obligation to update, republish or revise any forward-looking statement to reflect new information, future events or circumstances or to reflect the occurrence of unforeseen events, except as applicable law l ‘required.
LR Advisors LLC
E-mail: [email protected]
Telephone: (678) 570-6791
Contact person for media relations:
E-mail: [email protected]
SOURCE Hoth Therapeutics, Inc.